Sign In

Randall Moreadith, MD, PhD

Chief Development Officer

Dr. Randall Moreadith, MD, PhD, is a highly experienced CEO with a remarkable track record in drug development spanning over 25 years. He possesses a diverse skill set in developing a wide range of therapeutics, including biologics, small molecules, polymer therapeutics, antibody drug conjugates, gene therapy, and devices. Dr. Moreadith is a physician-scientist with a solid educational background, holding an MD with a focus on Internal Medicine - Cardiology from Duke University School of Medicine, a PhD in Molecular Genetics from Johns Hopkins University, and completing a fellowship in Genetics at Harvard University. He also has Executive Management training from SMU.

During his career, Dr. Moreadith has held key leadership positions in various prominent organizations. He served as the Chief Development Officer, President, and CEO at Serina Therapeutics, Inc., contributed as the Former Chief Development Officer at Nektar Therapeutics, acted as the Executive VP and Chief Medical Officer at Cardium Therapeutics, held the role of Chief Medical Officer at Renovis, Inc., and was appointed as the President and Chief Operating Officer at ThromboGenics, Ltd.

Highlights

Jul 18 · linkedin

On July 29th I presented a talk entitled "Overcoming Anti-PEG Antibody Responses to Increase Potency & Decrease Adverse Side Effects of mRNA-LNP Formulations".

The Serina LNP Laboratory has demonstrated that PEOZ-dma fails to elicit an IgM or IgG immune response upon repeat dosing in the rat - under the same conditions, PEG-dma (Acuitas, ALC-0159) elicits a robust immune response (both IgM & IgG). LNPs formulated with PEOZ-dma have other advantageous properties in addition to the absence of an immune response to the polymer lipid.

This finding is crucial because the PEG-lipids currently used in mRNA vaccines can elicit an anti-PEG antibody response. This response is associated with serious adverse events, including anaphylaxis, which can pose a life-threatening risk to patients.

You can read more here: www.serinatherapeutics.com   You can review my session details in the event program here: https://lnkd.in/e5rSqQin

#mRNASummit #WorldRNA #mRNAVaccines #mRNATherapeutics

May 2 · linkedin

3rd LNP Summit - Boston, MA

On Wednesday May 1st I had the privilege of moderating a panel discussion entitled "The Diary of an LNP Biotech CEO: From Concept to Clinic" with an exceptional group of executives. Chris Lai, Julien Couture-Senecal and Lin-Xian Li are emblematic of the amazing talent that is present in the LNP Community. From a start-up while still a PhD Doctoral Candidate (Azane Therapeutics) to a late-stage development company harnessing the power of AI and machine-learning (METiS Therapeutics) to develop the next generation of LNPs that will target tissues outside the liver - I can say the field is going to change the way we treat diseases dramatically in the next decade. We believe every class of nucleic acid is in play now.

Randall Moreadith, MD, PhD
Add to my network

Location

Huntsville, Alabama, United States